Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 15, 2026
Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
July 2, 2021
Related Post
-
-
BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
May 15, 2026
-
Intensity Therapeutics Recognized with GHP Magazine’s 2026 Healthcare & Pharmaceutical Award
May 14, 2026
-
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer’s Disease
May 14, 2026